Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $9.95 Consensus PT from Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.40.

A number of equities research analysts have issued reports on the company. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Friday, March 14th.

Allogene Therapeutics Trading Down 8.6 %

Shares of ALLO stock opened at $1.69 on Friday. Allogene Therapeutics has a 12-month low of $1.32 and a 12-month high of $4.63. The stock has a market capitalization of $354.35 million, a P/E ratio of -1.08 and a beta of 1.02. The firm’s 50 day moving average is $1.92 and its 200 day moving average is $2.30.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. As a group, equities analysts predict that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Insider Activity

In related news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the transaction, the executive vice president now directly owns 488,054 shares in the company, valued at approximately $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,866 shares of company stock worth $194,461 in the last three months. Company insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cibc World Markets Corp bought a new stake in Allogene Therapeutics in the 4th quarter valued at $26,000. PAX Financial Group LLC bought a new stake in shares of Allogene Therapeutics in the fourth quarter worth about $27,000. RPO LLC bought a new stake in shares of Allogene Therapeutics in the fourth quarter worth about $31,000. Caption Management LLC purchased a new stake in shares of Allogene Therapeutics in the fourth quarter worth about $32,000. Finally, Syon Capital LLC bought a new position in Allogene Therapeutics during the fourth quarter valued at approximately $39,000. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).